Order Article Reprints

Machado CB, de Pinho Pessoa FMC, da Silva EL, da Costa Pantoja L, Ribeiro RM, de Moraes Filho MO, de Moraes MEA, Montenegro RC, Burbano RMR, Khayat AS, et al. Kinase Inhibition in Relapsed/Refractory Leukemia and Lymphoma Settings: Recent Prospects into Clinical Investigations. Pharmaceutics. 2021; 13(10):1604. https://doi.org/10.3390/pharmaceutics13101604

Machado, Caio Bezerra, Flávia Melo Cunha de Pinho Pessoa, Emerson Lucena da Silva, Laudreísa da Costa Pantoja, Rodrigo Monteiro Ribeiro, Manoel Odorico de Moraes Filho, Maria Elisabete Amaral de Moraes, Raquel Carvalho Montenegro, Rommel Mário Rodriguez Burbano, André Salim Khayat, and et al. 2021. "Kinase Inhibition in Relapsed/Refractory Leukemia and Lymphoma Settings: Recent Prospects into Clinical Investigations" Pharmaceutics 13, no. 10: 1604. https://doi.org/10.3390/pharmaceutics13101604

Machado, C. B., de Pinho Pessoa, F. M. C., da Silva, E. L., da Costa Pantoja, L., Ribeiro, R. M., de Moraes Filho, M. O., de Moraes, M. E. A., Montenegro, R. C., Burbano, R. M. R., Khayat, A. S., & Moreira-Nunes, C. A. (2021). Kinase Inhibition in Relapsed/Refractory Leukemia and Lymphoma Settings: Recent Prospects into Clinical Investigations. Pharmaceutics, 13(10), 1604. https://doi.org/10.3390/pharmaceutics13101604